» Articles » PMID: 27460023

Considerations on Inhibition Approaches for Proinflammatory Functions of ADAM Proteases

Overview
Journal Platelets
Publisher Informa Healthcare
Specialty Hematology
Date 2016 Jul 28
PMID 27460023
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Proteases of the disintegrin and metalloproteinase (ADAM) family mediate the proteolytic shedding of various surface molecules including cytokine precursors, adhesion molecules, growth factors, and receptors. Within the vasculature ADAM10 and ADAM17 regulate endothelial permeability, transendothelial leukocyte migration, and the adhesion of leukocytes and platelets. In vivo studies show that both proteases are implicated in several inflammatory pathologies, for example, edema formation, leukocyte infiltration, and thrombosis. However, both proteases also contribute to developmental and regenerative processes. Thus, although ADAMs can be regarded as valuable drug targets in many aspects, the danger of severe side effects is clearly visible. To circumvent these side effects, traditional inhibition approaches have to be improved to target ADAMs at the right time in the right place. Moreover, the inhibitors need to be more selective for the target protease and if possible also for the substrate. Antibodies recognizing the active conformation of ADAMs or small molecules blocking exosites of ADAM proteases may represent inhibitors with the desired selectivities.

Citing Articles

Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.

Chen H, Wang C, Toh W, Lee H, Chung W, Chen C Clin Rev Allergy Immunol. 2023; 65(3):331-353.

PMID: 37897588 DOI: 10.1007/s12016-023-08973-1.


ADAM10 and ADAM17, Major Regulators of Chronic Kidney Disease Induced Atherosclerosis?.

Maas S, Donners M, van der Vorst E Int J Mol Sci. 2023; 24(8).

PMID: 37108478 PMC: 10139114. DOI: 10.3390/ijms24087309.


In Silico and Experimental ADAM17 Kinetic Modeling as Basis for Future Screening System for Modulators.

Bienstein M, Minond D, Schwaneberg U, Davari M, Yildiz D Int J Mol Sci. 2022; 23(3).

PMID: 35163294 PMC: 8835787. DOI: 10.3390/ijms23031368.


The role of S100B/RAGE-enhanced ADAM17 activation in endothelial glycocalyx shedding after traumatic brain injury.

Zou Z, Li L, Li Q, Zhao P, Zhang K, Liu C J Neuroinflammation. 2022; 19(1):46.

PMID: 35148784 PMC: 8832692. DOI: 10.1186/s12974-022-02412-2.


The Downregulation of ADAM17 Exerts Protective Effects against Cardiac Fibrosis by Regulating Endoplasmic Reticulum Stress and Mitophagy.

Guan C, Zhang H, Wang Y, Chen Z, Deng B, Qiu Q Oxid Med Cell Longev. 2021; 2021:5572088.

PMID: 34035876 PMC: 8118735. DOI: 10.1155/2021/5572088.